Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium in Patients with Age-Related Macular Degeneration and Stargardt’s Macular Dystrophy: Follow-Up of Two Open-Label Phase I/II Studies Two prospective Phase I/II studies were done to assess the primary endpoints safety and tolerability of subretinal transplantation of human embryonic stem cells-derived retinal pigment epithelium in nine patients with Stargardt’s macular dystrophy and nine with atrophic age-related macular degeneration. [Lancet] Abstract | Press Release T Cells Expressing CD19 Chimeric Antigen Receptors for Acute Lymphoblastic Leukemia in Children and Young Adults: A Phase I Dose-Escalation Trial Researchers aimed to define feasibility, toxicity, maximum tolerated dose, response rate, and biological correlates of response in children and young adults with refractory B-cell malignancies treated with CD19-chimeric antigen receptor T cells. [Lancet] Abstract | Press Release Myeloproliferative Neoplasms Can Be Initiated from a Single Hematopoietic Stem Cell Expressing JAK2-V617F Researchers demonstrate by limiting dilution and single-cell transplantations that myeloproliferative neoplasm (MPN) disease, manifesting either as erythrocytosis or thrombocytosis, can be initiated clonally from a single cell carrying JAK2-V617F. However, only a subset of mice reconstituted from single hematopoietic stem cells displayed MPN phenotype. [J Exp Med] Abstract A Phase I/IIa Follistatin Gene Therapy Trial for Becker Muscular Dystrophy In this Becker muscular dystrophy proof-of-principle clinical trial, a potent myostatin antagonist, follistatin, was used to inhibit the myostatin pathway. Extensive pre-clinical studies, using adeno-associated virus to deliver follistatin, demonstrated an increase in strength. [Mol Ther] Abstract | Press Release Murine and Human Tissue-Engineered Esophagus Form from Sufficient Stem/Progenitor Cells and Do Not Require Microdesigned Biomaterials Esophageal organoid units were isolated from murine or human esophagi and implanted on a polyglycolic acid/poly-L-lactic acid collagen-coated scaffold in adult allogeneic or immune-deficient mice. [Tissue Eng Part A] Abstract | Press Release Targeted Transplantation of Human Umbilical Cord Blood Endothelial Progenitor Cells with Immunomagnetic Nanoparticles to Repair Corneal Endothelium Defect A novel method of targeted cellular transplantation without permanent residence of cell carriers in the host was proposed. Human umbilical cord blood endothelial progenitor cells (UCB EPCs) were labeled with CD34 immunomagnetic nanoparticles. The UCB EPCs labeled with nanoparticles were transplanted into the anterior chamber of rabbits with magnet attraction. [Stem Cells Dev] Abstract Mesenchymal Stromal Cells Engineered to Produce IGF-I by Recombinant Adenovirus Ameliorate Liver Fibrosis in Mice Scientists analyzed the effect of applying insulin growth factor like-I (IGF-I) overexpressing mouse bone marrow-derived mesenchymal stromal cells (MSCs) on hepatic fibrosis. Liver fibrosis was ameliorated after single dose application of MSCs engineered to produce IGF-I when compared to MSCs engineered to produce GFP and/or recombinant IGF-I treatments. [Stem Cells Dev] Abstract Multipotent Mesenchymal Stromal Cells Synergize with Costimulation Blockade in the Inhibition of Immune Responses and the Induction of Foxp3+ Regulatory T Cells Mesenchymal stromal cell (MSCs) from C57BL/6 (H2b) mice were infused together with fully major histocompatibility complex-mismatched Balb/c allogeneic islets into the portal vein of diabetic H2b mice, which were subsequently treated with costimulation blockade for the first 10 days after transplantation. Mice receiving both recipient-type MSCs, CTLA4Ig, and anti-CD40L demonstrated indefinite graft acceptance, just as did most of the recipients receiving MSCs and CTLA4Ig. [Stem Cells Transl Med] Abstract Testing Stem Cell Therapy in a Rat Model of Inflammatory Bowel Disease: Role of Bone Marrow Stem Cells and Stem Cell Factor in Mucosal Regeneration Researchers explored the role of bone marrow mesenchymal stromal cells and soluble stem cell factor in gastrointestinal mucosa regeneration in a rat model of inflammatory bowel diseases. [PLoS One] Full Article Salvage Therapy with ARA-C and Gemtuzumab Ozogamicin in AML Patients Relapsing after Stem Cell Transplantation Researchers report their experience with ARA-C and gemtuzumab ozogamicin (GO) combination in relapsed post-stem cell transplantation acute myeloid leukemia (AML) patients. Therapy consisted of ARA-C for four days followed by one dose of GO 9 mg/m2 on day five and was supported by donor stem cells when possible. [Ann Hematol] Abstract |